Chelsea Therapeutics Settles Investor Class Action For $5.5M

Law360, New York (May 27, 2016, 6:56 PM EDT) -- Chelsea Therapeutics International Inc. has agreed to pay $5.5 million in cash to settle an investor’s putative securities class action stemming from alleged misstatements about its blood pressure drug Northera, the investor told a North Carolina federal court Friday.

Roman Zak, lead plaintiff in the case, asked the court in an unopposed motion to approve the class and sign off on the settlement, which was reached after a March meeting of both parties with Jed Melnick of Judicial Arbitration Mediation Services. Zak also asked for Faruqi & Faruqi LLP to be named as class counsel.

“Lead plaintiff believes that the claims...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!